NOTTINGHAM, UK – July 6, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, today announced two new scientific posters to be presented at the 2011 Controlled Release Society (CRS) meeting and exposition, July 30–August 3, Maryland, USA. The posters highlight the formulation and stabilization capabilities of recombinant albumin (rAlbumin) to safeguard the integrity of protein drug substances as well as the potential for combining hyaluronic acid (HA) and diclofenac sodium to extend drug release in osteoarthritis applications. For more information or to request a copy of the scientific posters, please visit booth #301 at the 2011 CRS meeting or www.biopharma.novozymes.com.
“Novozymes is delighted to present its latest study findings in the application of advanced drug delivery technology at the 2011 CRS meeting,” comments Dermot Pearson, Marketing Director at Novozymes Biopharma. “We are committed to developing compliant formulation solutions that ensure improved stability, solubility and half-life of biotherapeutics and we are delighted to demonstrate how these innovative products can streamline the drug development process.”
The first poster, entitled ‘Recombinant Albumin: A multipurpose excipient for formulation and stabilization of biotherapeutics’, examines rAlbumin as an effective stabilizing excipient for 3D7 and FC27 malaria antigen proteins in liquid formulations. The findings demonstrate the potential of rAlbumin to safeguard proteins’ integrity preventing aggregation, oxidation and non-specific binding.
The second poster is entitled ‘Compatibility between diclofenac sodium and hyaluronic acid and release of diclofenac sodium from hyaluronic acid-containing preparations towards the treatment of osteoarthritis’. The findings of the poster indicate that the addition of HA to diclofenac-containing commercial formulations can extend drug release from less than 15 minutes to 10 hours, offering new advances for future intra-articular preparations intended for the treatment of osteoarthritis.
For further information on Novozymes’ range of innovative drug delivery products or to request a copy of the scientific posters, please visit booth #301 at the 2011 CRS meeting or www.biopharma.novozymes.com.
###
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
Contact:
Novozymes Biopharma:
Sally Vernon, Customer Communications Manager SYKE@novozymes.com Tel. +44 115 955 3355
MEDIA CONTACTS
Europe
René Tronborg
Office: +45 4446 2274
Mobile: +45 3077 2274
retr@novozymes.com
China
Zhu Xiaoqing
Office: +86 106 298 7888+362
Mobile: +86 138 012 40590
xqzh@novozymes.com
US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
Brazil
Saionara Ribeiro de Paula
Office: +55 41 3641 1112
Mobile: +55 41 9971 7225
saio@novozymes.com
INVESTOR CONTACTS
Europe
Tobias Bjorklund
Office: +45 4446 8682
Mobile: +45 3077 8682
tobb@novozymes.com
US
Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565
tsbm@novozymes.com
“Novozymes is delighted to present its latest study findings in the application of advanced drug delivery technology at the 2011 CRS meeting,” comments Dermot Pearson, Marketing Director at Novozymes Biopharma. “We are committed to developing compliant formulation solutions that ensure improved stability, solubility and half-life of biotherapeutics and we are delighted to demonstrate how these innovative products can streamline the drug development process.”
The first poster, entitled ‘Recombinant Albumin: A multipurpose excipient for formulation and stabilization of biotherapeutics’, examines rAlbumin as an effective stabilizing excipient for 3D7 and FC27 malaria antigen proteins in liquid formulations. The findings demonstrate the potential of rAlbumin to safeguard proteins’ integrity preventing aggregation, oxidation and non-specific binding.
The second poster is entitled ‘Compatibility between diclofenac sodium and hyaluronic acid and release of diclofenac sodium from hyaluronic acid-containing preparations towards the treatment of osteoarthritis’. The findings of the poster indicate that the addition of HA to diclofenac-containing commercial formulations can extend drug release from less than 15 minutes to 10 hours, offering new advances for future intra-articular preparations intended for the treatment of osteoarthritis.
For further information on Novozymes’ range of innovative drug delivery products or to request a copy of the scientific posters, please visit booth #301 at the 2011 CRS meeting or www.biopharma.novozymes.com.
###
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
Contact:
Novozymes Biopharma:
Sally Vernon, Customer Communications Manager SYKE@novozymes.com Tel. +44 115 955 3355
MEDIA CONTACTS
Europe
René Tronborg
Office: +45 4446 2274
Mobile: +45 3077 2274
retr@novozymes.com
China
Zhu Xiaoqing
Office: +86 106 298 7888+362
Mobile: +86 138 012 40590
xqzh@novozymes.com
US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
Brazil
Saionara Ribeiro de Paula
Office: +55 41 3641 1112
Mobile: +55 41 9971 7225
saio@novozymes.com
INVESTOR CONTACTS
Europe
Tobias Bjorklund
Office: +45 4446 8682
Mobile: +45 3077 8682
tobb@novozymes.com
US
Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565
tsbm@novozymes.com
No comments:
Post a Comment